Stockscreener 앱 받기
1.66
1.71%
0.03
전일 마감가:
$1.63
열려 있는:
$1.61
하루 거래량:
13,520
Relative Volume:
0.18
시가총액:
$219.79M
수익:
-
순이익/손실:
-
주가수익비율:
-7.3876
EPS:
-0.2247
순현금흐름:
-
1주 성능:
+9.79%
1개월 성능:
-10.87%
6개월 성능:
-13.43%
1년 성능:
-37.44%
1일 변동 폭
$1.61
$1.6699
1주일 범위
$1.499
$1.73
52주 변동 폭
$1.32
$3.335
Immutep Limited Adr Stock (IMMP) Company Profile
IMMP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
1.6699 | 219.79M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.48 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.70 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.82 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.13 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.94 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-17 | 개시 | CapitalOne | Overweight |
| 2023-08-03 | 개시 | Robert W. Baird | Outperform |
| 2021-08-03 | 개시 | Ladenburg Thalmann | Buy |
| 2021-07-16 | 재개 | Maxim Group | Buy |
| 2018-09-28 | 개시 | B. Riley FBR | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
모두보기
Immutep Limited Adr 주식(IMMP)의 최신 뉴스
Immutep to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
Immutep Limited (ASX:IMM) Initiates Phase III Trial for Non-Small Cell Lung Cancer - thecapitalclub.com.au
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now? - AInvest
Immutep Limited (NASDAQ:IMMP) Shares Sold by Jane Street Group LLC - Defense World
Verition Fund Management LLC Has $57,000 Stock Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - The Manila Times
Immutep shares new cancer study results - Investing.com
Immutep Quarterly Activities Report Q1 FY25 - Yahoo Finance
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial - The Manila Times
Immutep reports steady progress in Q4 FY24 By Investing.com - Investing.com Australia
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer - GlobeNewswire
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 - GlobeNewswire
10 Best Australian Stocks To Buy - Yahoo Finance
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer - GlobeNewswire
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - Targeted Oncology
Best Penny Stocks To Buy For 2021? 5 Biotech Stocks To Watch - Penny Stocks
IMMPImmutep Latest Stock News & Market Updates - Stock Titan
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO - Yahoo Finance
A Full List of Australia ADRs - Investing.com Australia
Immutep (IMMP) Stock Price, News & Analysis - MarketBeat
Immutep Limited Adr (IMMP) 재무 분석
Immutep Limited Adr (IMMP)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.63%
자본화:
|
볼륨(24시간):